Clinical trials in East Syracuse, NY

17 recruiting studies have a site in or near East Syracuse, NY, New York.

Top conditions here

All conditions

Showing 17 of 17 studies

RecruitingPhase 3NCT07213674

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Sponsor: Amgen

East Syracuse, NY · New York, NY · +44 more sites

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Auburn, NY · Bay Shore, NY · Brooklyn, NY · +1147 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Buffalo, NY · East Syracuse, NY · New York, NY · +51 more sites

RecruitingPhase 3NCT07388524

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Sponsor: National Cancer Institute (NCI)

Buffalo, NY · Camillus, NY · East Syracuse, NY · +97 more sites

RecruitingPhase 3NCT07222800

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Sponsor: Pfizer

Albany, NY · Auburn, NY · Babylon, NY · +251 more sites

RecruitingPhase 1 / Phase 2NCT05319730

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Sponsor: Merck Sharp & Dohme LLC

East Syracuse, NY · New York, NY · +3 more sites

RecruitingPhase 2NCT06143956

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Sponsor: Eli Lilly and Company

Amherst, NY · East Syracuse, NY · Port Jefferson Station, NY · +47 more sites

RecruitingPhase 1 / Phase 2NCT06469944

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Sponsor: Merck Sharp & Dohme LLC

East Syracuse, NY · New York, NY · +6 more sites

RecruitingPhase 3NCT07743450

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Sponsor: Ascletis Pharma (China) Co., Limited

East Northport, NY · East Syracuse, NY · New Windsor, NY · +81 more sites

RecruitingPhase 3NCT06492616

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Sponsor: Stemline Therapeutics, Inc.

Brooklyn, NY · East Syracuse, NY · Ithaca, NY · +173 more sites

RecruitingPhase 1 / Phase 2NCT06445972

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Sponsor: Merck Sharp & Dohme LLC

East Syracuse, NY · New York, NY · +6 more sites

RecruitingPhase not listedNCT06880055

Shield Post-Approval Study Protocol

Sponsor: Guardant Health, Inc.

Camillus, NY · East Syracuse, NY · Fayetteville, NY · +66 more sites

RecruitingPhase 3NCT05812807

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Sponsor: Alliance for Clinical Trials in Oncology

Bay Shore, NY · Brooklyn, NY · +825 more sites

RecruitingPhase 1 / Phase 2NCT04657068

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Sponsor: Artios Pharma Ltd

East Syracuse, NY · Lake Success, NY · +39 more sites

RecruitingPhase 3NCT05641688

[18F]PI-2620 Phase 3 Histopathological Study

Sponsor: Lantheus Biosciences Ltd.

East Syracuse, NY · Syracuse, NY · +23 more sites

RecruitingPhase 3NCT04852887

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Sponsor: NRG Oncology

Astoria, NY · Bay Shore, NY · Binghamton, NY · +809 more sites

RecruitingPhase not listedNCT05236114

GEMINI-NSCLC: NSCLC Biomarker Study

Sponsor: Tempus AI

Albany, NY · East Syracuse, NY · Ithaca, NY · +55 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.